Kovoor, Joshua G.
Chow, Clara K.
Salam, Abdul http://orcid.org/0000-0002-5870-7936
Webster, Ruth
Shiel, Louise
Nelson, Mark R.
Affandi, Jacquita S.
Hay, Peter
Burke, Michael http://orcid.org/0000-0001-7641-4435
Figtree, Gemma A.
Usherwood, Tim
Reid, Christopher M.
Schlaich, Markus P. http://orcid.org/0000-0002-1765-0195
Rodgers, Anthony
Atkins, Emily R. http://orcid.org/0000-0003-2522-3510
Article History
Received: 14 December 2023
Revised: 19 April 2024
Accepted: 22 April 2024
First Online: 14 May 2024
Competing interests
: George Health Enterprises, the social enterprise arm of The George Institute for Global Health, has applied for patents in this research area, on which CKC and AR are named as inventors; George Health Enterprises has also received investment to develop fixed-dose combinations containing aspirin, statins, and BP-lowering drugs. MRN served on a Novartis Advisory Board unrelated to the work published here. GF is supported by a National Health and Medical Research Council Practitioner Fellowship (grant number APP11359290), Heart Research Australia, and the New South Wales Office of Health and Medical Research. MPS has received consulting fees, and/or travel and research support from Medtronic, Abbott, Novartis, Servier, Pfizer, and Boehringer-Ingelheim.
: Ethical approval was obtained from the Western Sydney Local Health Network Human Research Ethics Committee (HREC/15/WMEAD/422).